Investigation of the influence of the human microbiome on the pathogenesis and recurrence probability of giant cell arteritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032993

Enrollment

100

Registered

2024-02-16

Start date

2024-02-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M31.6

Interventions

Group 1: Diagnosis of Giant cell arthritis Study inclusion at initial diagnosis At diagnosis collection of the following parameters: clinical examination, questionnaires to for relevant medical infor

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of giant cell arteritis

Exclusion criteria

Exclusion criteria: chronic infection (viral, funghi, bacteria) including HIV, Hepatitis B/C acute infection with usage of antibiotics less then 90 days before screening major gastro-intestinal surgery 109 KBE per day) <90 days before screening not controlled Diabetes mellitus Malignancy within one year (except for squamous skin - and basal skin carcinoma without metastasis, cervix carcinoma with curative surgery, CTCL) known abuse of alcohol oder drugs.

Design outcomes

Primary

Measure	Time frame
Significant differences in the composition of the microbiome	—

Secondary

Measure	Time frame
Influence of the microbiome on therapy response e.g. increased probability of recurrence with accumulation of specific microbiome species	—

Countries

Germany

Contacts

Public ContactValentin Sebastian Schäfer

Universitätsklinikum Bonn

valentin.schaefer@ukbonn.de+4922817050

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026